L
Lakshmanane Premkumar
Researcher at University of North Carolina at Chapel Hill
Publications - 78
Citations - 6210
Lakshmanane Premkumar is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 20, co-authored 55 publications receiving 3911 citations. Previous affiliations of Lakshmanane Premkumar include Weizmann Institute of Science & Sanford-Burnham Institute for Medical Research.
Papers
More filters
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Journal ArticleDOI
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.
Jose Mateus,Alba Grifoni,Alison Tarke,John Sidney,Sydney I. Ramirez,Sydney I. Ramirez,Jennifer M. Dan,Jennifer M. Dan,Zoe C Burger,Stephen A. Rawlings,Davey M. Smith,Elizabeth J. Phillips,Simon Mallal,Marshall Lammers,Paul Rubiro,Lorenzo Quiambao,Aaron Sutherland,Esther Dawen Yu,Ricardo da Silva Antunes,Jason A. Greenbaum,April Frazier,Alena J. Markmann,Lakshmanane Premkumar,Aravinda M. de Silva,Bjoern Peters,Bjoern Peters,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette,Daniela Weiskopf +30 more
TL;DR: A range of preexisting memory CD4+ T cells that are cross-reactive with comparable affinity to SARS-CoV-2 and the common cold coronaviruses human coronavirus (HCoV)-OC43, H coV-229E, H CoV-NL63, and HCov-HKU1 are demonstrated.
Journal ArticleDOI
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Lakshmanane Premkumar,Bruno Segovia-Chumbez,Ramesh Jadi,David R. Martinez,Rajendra Raut,Alena J. Markmann,Caleb Cornaby,Luther A. Bartelt,Susan R. Weiss,Yara A. Park,Caitlin E. Edwards,Eric T. Weimer,Erin M. Scherer,Nadine Rouphael,Srilatha Edupuganti,Daniela Weiskopf,Longping V. Tse,Yixuan J. Hou,David M. Margolis,Alessandro Sette,Alessandro Sette,Matthew H. Collins,John L. Schmitz,Ralph S. Baric,Aravinda M. de Silva +24 more
TL;DR: Results, which reveal the early kinetics of Sars-CoV-2 antibody responses, support using the RBD antigen in serological diagnostic assays and RBD-specific antibody levels as a correlate of SARS-Co V-2 neutralizing antibodies in people.
Journal ArticleDOI
Whole-Exome-Sequencing-Based Discovery of Human FADD Deficiency
Alexandre Bolze,Minji Byun,David McDonald,Neil V. Morgan,Avinash Abhyankar,Lakshmanane Premkumar,Anne Puel,Chris M. Bacon,Frédéric Rieux-Laucat,K K Pang,Alison Britland,Laurent Abel,Laurent Abel,Andrew J. Cant,Andrew J. Cant,Eamonn R. Maher,Stefan J. Riedl,Sophie Hambleton,Sophie Hambleton,Jean-Laurent Casanova,Jean-Laurent Casanova +20 more
TL;DR: A homozygous missense mutation in FADD is identified, encoding the Fas-associated death domain protein (FADD), in the patients, and this FADD mutation decreases steady-state protein levels and impairs Fas-dependent apoptosis in vitro, accounting for biological ALPS phenotypes in vivo.
Journal ArticleDOI
Zika virus infection enhances future risk of severe dengue disease
Leah C. Katzelnick,César Narvaez,Sonia Arguello,Brenda Lopez Mercado,Damaris Collado,Oscarlett Ampie,Douglas Elizondo,Tatiana Miranda,Fausto A. Bustos Carillo,Juan Carlos Mercado,Krista Latta,Amy Schiller,Bruno Segovia-Chumbez,Sergio R. Ojeda,Nery Sanchez,Miguel Plazaola,Josefina Coloma,M. Elizabeth Halloran,M. Elizabeth Halloran,Lakshmanane Premkumar,Aubree Gordon,Federico Narvaez,Aravinda M. de Silva,Guillermina Kuan,Angel Balmaseda,Eva Harris +25 more
TL;DR: This study investigated prospective pediatric cohorts in Nicaragua that experienced sequential DENV1 to -3, Zika (2004 to 2015), Zika (2016 to 2017), and DENV2 (2018 to 2020) epidemics and found that prior immunity to Zika virus increases the risk of severe dengue disease via cross-reacting antibodies.